August 29, 2008


Schering-Plough and Pfizer deal gets the nod


The European Commission has cleared Pfizer's proposed acquisition of certain animal health assets of Schering-Plough.


The executive body cleared the proposal after examining the acquisiton and concluding that the proposed transaction would not significantly impede competition in the European Economic Area (EEA). 


Pfizer is a global healthcare company, active in human and animal health products. The Schering-Plough (SP Assets) comprise a broad range of products for both companion and farm animals including various vaccines.


Schering-Plough is pursuing the sale of these assets following commitments it made in the acquisition of Organon BS.


The overlaps between the activities of Pfizer and the SP Assets are limited in most markets.


The Commission's decision indicated that the new entity would continue to face significant competition in the animal health segment and that farmers and veterinarians across the EEA would continue to have access to alternative suppliers.

Video >

Follow Us